FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice

Diabetologia

Volumn 58, Issue 10, 2015, Pages 2414-2423

  Stemmer, Kerstin ^a   Zani, Fabio ^a   Habegger, Kirk M ^b   Neff, Christina ^a   Kotzbeck, Petra ^a   Bauer, Michaela ^a   Yalamanchilli, Suma ^a   Azad, Ali ^c   Lehti, Maarit ^d   Martins, Paulo J F ^c   Müller, Timo D ^a   Pfluger, Paul T ^a   Seeley, Randy J ^e  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d LIKES RESEARCH CENTER FOR SPORT AND HEALTH SCIENCES   (Finland)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Energy expenditure; Fibroblast growth factor 21; Glucose homeostasis; Ketogenic diets; Protein starvation; Tumour suppression

Indexed keywords

CARBOHYDRATE; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR; GLUCOSE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CONTROLLED STUDY; ENERGY EXPENDITURE; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; KETOACIDOSIS; KETOGENIC DIET; KWASHIORKOR; LEWIS LUNG CARCINOMA CELL; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ANIMAL; DIET THERAPY; GENETICS; HOMEOSTASIS; KNOCKOUT MOUSE; LIVER; NEOPLASM; PROTEIN DEFICIENCY;

ADIPOSE TISSUE; ANIMALS; FIBROBLAST GROWTH FACTORS; GLUCOSE; HOMEOSTASIS; KETOGENIC DIET; KETOSIS; LIVER; MICE; MICE, KNOCKOUT; NEOPLASMS; PROTEIN DEFICIENCY;

EID: 84942191180     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3668-7     Document Type: Article

References (46)

1. Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA (2003) A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab 88:1617–1623
2. Foster GD, Wyatt HR, Hill JO et al (2003) A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348:2082–2090
3. Dashti HM, Mathew TC, Khadada M et al (2007) Beneficial effects of ketogenic diet in obese diabetic subjects. Mol Cell Biochem 302:249–256
4. Acheson KJ (2010) Carbohydrate for weight and metabolic control: where do we stand? Nutrition 26:141–145
5. Kessler SK, Neal EG, Camfield CS, Kossoff EH (2011) Dietary therapies for epilepsy: future research. Epilepsy Behav 22:17–22
6. Paoli A, Bianco A, Damiani E, Bosco G (2014) Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed Res Int 2014:474296
7. Nebeling LC, Miraldi F, Shurin SB, Lerner E (1995) Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14:202–208
8. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P (2003) Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 89:1375–1382
9. Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P (1807) Metabolic management of brain cancer. Biochim Biophys Acta 2011:577–594
10. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426–437
11. Inagaki T, Dutchak P, Zhao G et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415–425
12. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150:4931–4940
13. Potthoff MJ, Inagaki T, Satapati S et al (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 106:10853–10858
14. Dutchak PA, Katafuchi T, Bookout AL et al (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148:556–567
15. Hotta Y, Nakamura H, Konishi M et al (2009) Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150:4625–4633
16. Adams AC, Coskun T, Cheng CC, O’Farrell LS, Dubois SL, Kharitonenkov A (2013) Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol Metab 2:205–214
17. Galman C, Lundasen T, Kharitonenkov A et al (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8:169–174
18. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F (2009) Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 94:3594–3601
19. Dushay J, Chui PC, Gopalakrishnan GS et al (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456–463
20. Coskun T, Bina HA, Schneider MA et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018–6027
21. Muller TD, Sullivan LM, Habegger K et al (2012) Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 18:383–393
22. Kharitonenkov A, Beals JM, Micanovic R et al (2013) Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 8:e58575
23. Adams AC, Halstead CA, Hansen BC et al (2013) LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One 8:e65763
24. Gimeno RE, Moller DE (2014) FGF21-based pharmacotherapy—potential utility for metabolic disorders. Trends Endocrinol Metab 25:303–311
25. Kharitonenkov A, Adams AC (2014) Inventing new medicines: the FGF21 story. Mol Metab 3:221–229
26. Bielohuby M, Menhofer D, Kirchner H et al (2011) Induction of ketosis in rats fed low-carbohydrate, high-fat diets depends on the relative abundance of dietary fat and protein. Am J Physiol Endocrinol Metab 300:E65–E76
27. Jornayvaz FR, Jurczak MJ, Lee HY et al (2010) A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am J Physiol Endocrinol Metab 299:E808–E815
28. Kennedy AR, Pissios P, Otu H et al (2007) A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab 292:E1724–E1739
29. Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203–206
30. Stemmer K, Kotzbeck P, Zani F et al (2015) Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. Int J Obes (Lond) 39:791–797
31. Wiese TJ, Lambeth DO, Ray PD (1991) The intracellular distribution and activities of phosphoenolpyruvate carboxykinase isozymes in various tissues of several mammals and birds. Comp Biochem Physiol B 100:297–302
32. Stark R, Pasquel F, Turcu A et al (2009) Phosphoenolpyruvate cycling via mitochondrial phosphoenolpyruvate carboxykinase links anaplerosis and mitochondrial GTP with insulin secretion. J Biol Chem 284:26578–26590
33. Stemmer K, Bielohuby M, Grayson BE et al (2013) Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats. Endocrinology 154:2015–2024
34. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
35. Lecker SH, Jagoe RT, Gilbert A et al (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18:39–51
36. Yoon JC, Puigserver P, Chen G et al (2001) Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:131–138
37. De Sousa-Coelho AL, Marrero PF, Haro D (2012) Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J 443:165–171
38. Pissios P, Hong S, Kennedy AR, Prasad D, Liu FF, Maratos-Flier E (2013) Methionine and choline regulate the metabolic phenotype of a ketogenic diet. Mol Metab 2:306–313
39. Laeger T, Henagan TM, Albarado DC et al (2014) FGF21 is an endocrine signal of protein restriction. J Clin Invest 124:3913–3922
40. Sarruf DA, Thaler JP, Morton GJ et al (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59:1817–1824
41. Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250–259
42. Owen BM, Ding X, Morgan DA et al (2014) FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 20:670–677
43. Fisher FM, Estall JL, Adams AC et al (2011) Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152:2996–3004
44. Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627–1635
45. Kong LJ, Feng W, Wright M et al (2013) FGF21 suppresses hepatic glucose production through the activation of atypical protein kinase Ciota/lambda. Eur J Pharmacol 702:302–308
46. Murata Y, Nishio K, Mochiyama T et al (2013) Fgf21 impairs adipocyte insulin sensitivity in mice fed a low-carbohydrate, high-fat ketogenic diet. PLoS One 8:e69330